Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. (14th July 2019)

• Record Type: Journal Article
• Authors: Foley, Stephen; Choudhury, Nurul; Huang, Moses; Stari, Anny; Nazir, Jameel; Freeman, Robert
• Is Part Of: International journal of urology. Volume 26:Number 9(2019)
• Page Start: 890
• Page End: 896
• Publication Date: 2019-07-14
• Subjects: aged -- medication adherence -- mirabegron -- overactive -- quality of life -- urinary bladder; Urology -- Periodicals; Genitourinary organs -- Periodicals; Urologic Diseases -- Periodicals; 616.6005
• DOI: 10.1111/iju.14050
• Languages: English
• ISSNs: 0919-8172

Abstract

Abstract : Objectives: To describe quality of life outcomes in patients with overactive bladder aged ≥65 years receiving mirabegron, a β3‐adrenoreceptor agonist (BELIEVE). Methods: BELIEVE was a European, prospective, non‐interventional, real‐world study of 848 patients with overactive bladder prescribed mirabegron in clinical practice. Overactive bladder questionnaire subscales were prespecified primary end‐points, analyzed in the full analysis set (patients completing the questionnaire at baseline and ≥1 follow‐up visit) and per protocol set (patients still taking mirabegron at 10–12 months) using accepted standards for minimally important differences (10 points). Results: Nearly half of the patients in the full analysis set (380/796 [47.7%]) and per protocol set (224/452 [49.6%]) were aged ≥65 years. Similar proportions of patients aged ≥65 years (224/407; 55.0%) and <65 years (228/441; 51.7%) were taking mirabegron at 10–12 months. Mean symptom bother scores improved from baseline to month 10–12 in older patients (full analysis set 52.4 to 32.9; per protocol set 51.6 to 30.4) and younger patients (full analysis set 52.2 to 27.4; per protocol set 47.8 to 23.7). Proportions of older/younger patients with improvement in symptom bother were similar (full analysis set 52.1%/52.9%; per protocol set 70.1%/72.4%, respectively). Mean total quality of life scores improved in older patients (full analysis set 60.7–75.9; per protocol set 61.1–77.5) and younger patients (full analysis set 54.9 to 77.6; per protocol set 56.8 to 80.1). No unexpected safety issues were observed. Conclusions: Patients aged ≥65 years receiving mirabegron in clinical practice reported clinically meaningful improvements in quality of life.